Mitomycin Medac (Mitomycin)

Mitomycin acts by forming covalent cross‑links between DNA strands, which prevents DNA replication and transcription. This DNA damage triggers cell‑cycle arrest and apoptosis, preferentially affecting rapidly dividing cancer cells while sparing most normal tissues.

The dose of mitomycin is individualized by the treating physician based on the specific cancer type, treatment setting (intravenous or intravesical), patient weight, renal function and concurrent therapies. Only a qualified prescriber can determine the appropriate regimen.

The safety of mitomycin in pregnancy and lactation is not established. It is classified as having an unknown pregnancy category, and the drug may cross the placenta or be excreted in breast milk. Use is generally avoided unless the potential benefit justifies the potential risk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Mitomycin is distinguished by its ability to create DNA cross‑links under hypoxic conditions, which can make it effective in tumours resistant to other alkylators. Compared with agents like cyclophosphamide, mitomycin often requires careful renal monitoring and has a different toxicity profile, including a higher risk of pulmonary complications.

Mitomycin Medac should be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. The product must be kept in its original container until reconstitution, and handling should follow aseptic techniques to maintain sterility.

The drug is supplied as a sterile powder for reconstitution. For bladder cancer, it is instilled directly into the bladder (intravesical) after tumor resection. For systemic disease, the reconstituted solution is given intravenously, typically over a short infusion period under close medical supervision.

Serious risks include severe bone‑marrow suppression leading to infection or bleeding, pulmonary toxicity such as interstitial pneumonitis, acute renal failure, hemolytic‑uremic syndrome, and rare but life‑threatening allergic reactions. Patients should be monitored closely for signs of these complications.

Mitomycin is contraindicated in patients with known hypersensitivity to the drug, those with severe renal impairment, and individuals who are pregnant unless the therapeutic benefit outweighs the risk. Caution is also advised for patients with pre‑existing bone‑marrow suppression or severe pulmonary disease.